High Treatment Adherence and Low Ultrafiltration Rates on Four Day per Week Home Hemodialysis with Tablo

Michael Aragon, MD[1], Glenn Chertow, MD[2], Sarah Prichard, MD[3], Troy Plumb, MD[4]

1 Outset Medical, San Jose, CA; 2 Stanford School of Medicine, Stanford, CA; 3 Western University, London, Ontario, Canada; 4 University of Nebraska Medical Center, Omaha, NE

BACKGROUND:

The Tablo® Hemodialysis System is an all-in-one system featuring:

- An Integrated Water Purification System
- On-Demand Dialysate Production
- A Simplified User Interface
- Two-way Wireless Communication

The recently published Investigational Device Exemption (IDE) trial using the Tablo system at home reported:

- Achievement of all primary and secondary efficacy endpoints.
- Achievement of all primary and secondary safety endpoints.

Ultrafiltration (UF) rates >10 mL/kg/hr have been associated with increased all cause and cardiovascular mortality.

OBJECTIVE:

Present UF rate and adherence to protocol of participants performing dialysis treatments 4 times per week with Tablo In-Center and In-Home.

METHODS:

Participants were prescribed dialysis 4 times per week on Tablo during the following phases:

- 8 weeks In-Center, 4 weeks of transition, and 8 weeks In-Home.

Prior modality, adherence to therapy and average ultrafiltration rates were recorded.

RESULTS:

28 of 30 (93%) enrolled participants completed all phases

- 15 previously In-Center (PIC) and 13 previously In-Home (PIH) participants

Adherence to therapy was 95% In-Center and 99% In-Home.

UF rate <10 mL/kg/hr over all periods
- 100% of previously In-Center participants
- 92% of previously In-Home participants

UF rate <8mL/kg/hr over all periods
- 80% of previously In-Center participants
- 77% of previously In-Home participants

Tablo® Hemodialysis System

Table 1

% of participants with Average UF Rate of <8 mL/hr/kg and <10 mL/hr/kg across both the In-Center and In-Home treatment periods.


Table 2

	Total # of Treatments Completed per Group		Total # of Treatments Completed	Total Possible # of Treatments	% Adherence to Protocol
IN-CENTER	PIC 457	PIH 396	853	896	95%
IN-HOME	PIC 475	PIH 408	883	896	99%

Table 3

PATIENT CHARACTERISTICS	PIH n (%)	PIC n (%)
Total	13	15
GENDER		
Male	8 (62)	10 (67)
ETHNICITY		
Not Hispanic or Latino	9 (69)	11 (73)
Hispanic or Latino	3 (23)	4 (27)
Not Reported	1 (8)	0 (0)
RACE		
White	8 (62)	8 (53)
Black or African American	5 (38)	7 (47)
AGE		
Avg ± SD	50 ± 13	55 ± 11
WEIGHT		
Avg ± SD	92 ± 17	97 ± 17
ACCESS		
Fistula	9 (69)	12 (80)
Catheter	2 (15)	2 (13)
Graft	2 (15)	1 (7)
PRIMARY CAUSE OF ESKD		
Diabetes	4 (31)	9 (60)
Polycystic Kidney Disease	2 (15)	0 (0)
Glomerulonephritis	1 (8)	1 (7)
Hypertension	1 (8)	0 (0)
Other	5 (38)	5 (33)

CONCLUSION:

Patients on Tablo 4 times per week can achieve a high adherence to therapy.

Ultrafiltration rates associated with improved outcomes can be achieved on Tablo at 4 times per week.

.Outset

CONTACT FOR CORRESPONDENCE: Michael Aragon, MD
maragon@outsetmedical.com